Cargando…

Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial

OBJECTIVE: To evaluate the efficacy and safety of Chuanxiong Qingnao Granule (CQG) to treat migraine. METHOD: This study was a randomized, double-blind, placebo-controlled trial. All migraineurs were recruited and randomly assigned into a treatment group treated with CQG and a control group treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yi-Fan, Hu, Hui-Min, Wang, Bo-Ning, Zhang, Yi, Liu, Xing, Mao, Peng, Fan, Bi-Fa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716194/
https://www.ncbi.nlm.nih.gov/pubmed/34976097
http://dx.doi.org/10.1155/2021/6203999
_version_ 1784624270258733056
author Li, Yi-Fan
Hu, Hui-Min
Wang, Bo-Ning
Zhang, Yi
Liu, Xing
Mao, Peng
Fan, Bi-Fa
author_facet Li, Yi-Fan
Hu, Hui-Min
Wang, Bo-Ning
Zhang, Yi
Liu, Xing
Mao, Peng
Fan, Bi-Fa
author_sort Li, Yi-Fan
collection PubMed
description OBJECTIVE: To evaluate the efficacy and safety of Chuanxiong Qingnao Granule (CQG) to treat migraine. METHOD: This study was a randomized, double-blind, placebo-controlled trial. All migraineurs were recruited and randomly assigned into a treatment group treated with CQG and a control group treated with a placebo. The whole research process included a 4-week baseline, 12-week intervention, and 12-week follow-up. The primary outcome was responder rate, defined as the percentage of migraineurs with 50% or more reduction in the frequency of migraine attack during treatment and posttreatment period compared with the baseline. The secondary outcomes were the number of migraine days, migraine attack frequency, visual analogue scale (VAS), Fatigue Severity Scale (FSS), Hamilton Depression Scale (HAMD), and Migraine Disability Assessment (MIDAS). RESULTS: A total of 346 migraineurs completed the research and were included in the intention-treatment analyses. The response rates differed significantly between the treatment group and the control group (71.5% vs. 12.1% at week 12 and 83.1% vs. 3.4% at week 24). Attack frequency, days of headache attack, VAS, FSS, HAMD, and MIDAS decreased at week 12 in both groups with more reduction in the treatment group (P < 0.001). No severe adverse events were observed in this trial. CONCLUSION: Chuanxiong Qingnao Granule can significantly improve headache symptoms in patients with migraine while improving disability, fatigue, and depression with a good safety profile.
format Online
Article
Text
id pubmed-8716194
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-87161942021-12-30 Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial Li, Yi-Fan Hu, Hui-Min Wang, Bo-Ning Zhang, Yi Liu, Xing Mao, Peng Fan, Bi-Fa Evid Based Complement Alternat Med Research Article OBJECTIVE: To evaluate the efficacy and safety of Chuanxiong Qingnao Granule (CQG) to treat migraine. METHOD: This study was a randomized, double-blind, placebo-controlled trial. All migraineurs were recruited and randomly assigned into a treatment group treated with CQG and a control group treated with a placebo. The whole research process included a 4-week baseline, 12-week intervention, and 12-week follow-up. The primary outcome was responder rate, defined as the percentage of migraineurs with 50% or more reduction in the frequency of migraine attack during treatment and posttreatment period compared with the baseline. The secondary outcomes were the number of migraine days, migraine attack frequency, visual analogue scale (VAS), Fatigue Severity Scale (FSS), Hamilton Depression Scale (HAMD), and Migraine Disability Assessment (MIDAS). RESULTS: A total of 346 migraineurs completed the research and were included in the intention-treatment analyses. The response rates differed significantly between the treatment group and the control group (71.5% vs. 12.1% at week 12 and 83.1% vs. 3.4% at week 24). Attack frequency, days of headache attack, VAS, FSS, HAMD, and MIDAS decreased at week 12 in both groups with more reduction in the treatment group (P < 0.001). No severe adverse events were observed in this trial. CONCLUSION: Chuanxiong Qingnao Granule can significantly improve headache symptoms in patients with migraine while improving disability, fatigue, and depression with a good safety profile. Hindawi 2021-12-22 /pmc/articles/PMC8716194/ /pubmed/34976097 http://dx.doi.org/10.1155/2021/6203999 Text en Copyright © 2021 Yi-Fan Li et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Li, Yi-Fan
Hu, Hui-Min
Wang, Bo-Ning
Zhang, Yi
Liu, Xing
Mao, Peng
Fan, Bi-Fa
Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial
title Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial
title_full Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial
title_fullStr Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial
title_full_unstemmed Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial
title_short Efficacy and Safety of Chuanxiong Qingnao Granule in Patients with Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial
title_sort efficacy and safety of chuanxiong qingnao granule in patients with migraine: a randomized, double-blind, placebo-controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716194/
https://www.ncbi.nlm.nih.gov/pubmed/34976097
http://dx.doi.org/10.1155/2021/6203999
work_keys_str_mv AT liyifan efficacyandsafetyofchuanxiongqingnaogranuleinpatientswithmigrainearandomizeddoubleblindplacebocontrolledtrial
AT huhuimin efficacyandsafetyofchuanxiongqingnaogranuleinpatientswithmigrainearandomizeddoubleblindplacebocontrolledtrial
AT wangboning efficacyandsafetyofchuanxiongqingnaogranuleinpatientswithmigrainearandomizeddoubleblindplacebocontrolledtrial
AT zhangyi efficacyandsafetyofchuanxiongqingnaogranuleinpatientswithmigrainearandomizeddoubleblindplacebocontrolledtrial
AT liuxing efficacyandsafetyofchuanxiongqingnaogranuleinpatientswithmigrainearandomizeddoubleblindplacebocontrolledtrial
AT maopeng efficacyandsafetyofchuanxiongqingnaogranuleinpatientswithmigrainearandomizeddoubleblindplacebocontrolledtrial
AT fanbifa efficacyandsafetyofchuanxiongqingnaogranuleinpatientswithmigrainearandomizeddoubleblindplacebocontrolledtrial